Upstream Bio Conference Call Summary Company Overview - Company: Upstream Bio (NasdaqGS:UPB) - Focus: Clinical stage company developing a monoclonal antibody antagonist of the receptor for TSLP, named verekitug [2][3] Key Points on Drug Development - Current Trials: Verekitug is in placebo-controlled Phase 2 trials for severe asthma and other indications [2] - Efficacy Data: Recent Phase 2 trial (VALIANT) showed a statistically significant reduction in asthma exacerbation rates across all tested dose regimens, with the high dose (100 mg Q12W) achieving a 56% reduction [4][5] - Dosing Strategy: The drug is designed for quarterly dosing, which is expected to provide a competitive advantage over existing treatments [6][8] - Potency: Verekitug is approximately 300 times more potent than Tezepelumab, allowing for flexible dosing strategies [8][19] Phase 3 Preparation - Data Analysis: The company is currently analyzing Phase 2 data to inform dose selection for Phase 3 trials, aiming to maximize efficacy while minimizing dosing frequency [3][7] - Regulatory Alignment: The company plans to finalize its Phase 3 strategy after discussions with regulators, expected to occur in Q3 2026 [12][20] Long-term Extension Study - Patient Retention: Over 90% of patients from the Phase 2 trial have rolled over into the long-term extension study, allowing for extended follow-up and additional data collection [17][18] Competitive Landscape - Market Positioning: Upstream Bio differentiates itself by targeting the receptor for TSLP, while many competitors focus on the ligand. The company believes understanding the pharmacology of its molecule is crucial for successful Phase 3 trials [19][20] - Emerging Competition: The company is aware of competitors like Generate and Glaxo, but emphasizes its unique approach and data-driven strategy [19][21] Market for Biologics in Asthma - Market Dynamics: The asthma treatment market is converging around a limited set of targets (TSLP, IL-13, IL-5, IgE). The company aims to innovate within this space by delivering a differentiated clinical profile [23][24] - Patient Preferences: Quarterly dosing is viewed favorably, and any reduction in efficacy could lead to decreased patient preference for less frequent dosing [25] COPD Opportunity - Trial Enrollment: Enrollment in the VENTURE COPD trial is over 60%. The company is considering potential changes to the study based on new data from the asthma trials [27][32] - Target Population: The focus is on patients with an eosinophilic phenotype, as they are expected to respond best to Type 2 immunomodulators [32][36] Financial Position - Cash Reserves: The company ended the last quarter with $341 million in cash, providing a runway through 2027 to support ongoing and future trials [50] Future Catalysts - Upcoming Events: The company plans to initiate Phase 3 trials for severe asthma and CRSwNP by the beginning of next year, with further updates on the COPD program expected as data becomes available [41][42] Device Development - Formulation and Delivery: The company has developed a highly concentrated formulation (200 mg/mL) to facilitate a single injection delivery system, which is crucial for patient comfort and compliance [42][43]
Upstream Bio (NasdaqGS:UPB) 2026 Conference Transcript